- Home
- PRZO vs ALLR Comparison
PRZO vs ALLR Comparison
Compare PRZO & ALLR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRZO
- ALLR
- Stock Information
- Founded
- PRZO 2014
- ALLR 2004
- Country
- PRZO Israel
- ALLR United States
- Employees
- PRZO N/A
- ALLR N/A
- Industry
- PRZO
- ALLR Biotechnology: Pharmaceutical Preparations
- Sector
- PRZO
- ALLR Health Care
- Exchange
- PRZO Nasdaq
- ALLR Nasdaq
- Market Cap
- PRZO 14.8M
- ALLR 13.3M
- IPO Year
- PRZO 2023
- ALLR N/A
- Fundamental
- Price
- PRZO $1.29
- ALLR $0.93
- Analyst Decision
- PRZO
- ALLR
- Analyst Count
- PRZO 0
- ALLR 0
- Target Price
- PRZO N/A
- ALLR N/A
- AVG Volume (30 Days)
- PRZO 1.5M
- ALLR 453.6K
- Earning Date
- PRZO 03-21-2025
- ALLR 08-04-2025
- Dividend Yield
- PRZO N/A
- ALLR N/A
- EPS Growth
- PRZO N/A
- ALLR N/A
- EPS
- PRZO N/A
- ALLR N/A
- Revenue
- PRZO $932,154.00
- ALLR N/A
- Revenue This Year
- PRZO N/A
- ALLR N/A
- Revenue Next Year
- PRZO N/A
- ALLR N/A
- P/E Ratio
- PRZO N/A
- ALLR N/A
- Revenue Growth
- PRZO 50.22
- ALLR N/A
- 52 Week Low
- PRZO $0.49
- ALLR $0.61
- 52 Week High
- PRZO $3.16
- ALLR $14.25
- Technical
- Relative Strength Index (RSI)
- PRZO 63.22
- ALLR 52.04
- Support Level
- PRZO $1.10
- ALLR $0.80
- Resistance Level
- PRZO $1.40
- ALLR $0.92
- Average True Range (ATR)
- PRZO 0.10
- ALLR 0.06
- MACD
- PRZO 0.01
- ALLR 0.01
- Stochastic Oscillator
- PRZO 79.40
- ALLR 74.66
About PRZO ParaZero Technologies Ltd.
ParaZero Technologies Ltd is an aerospace company that is focused on drone safety systems and engaged in the business of designing, developing, and providing autonomous parachute safety systems for commercial drones, also known as unmanned aerial systems. The ParaZero SafeAir system of the company applies real-time data analytics to identify and mitigate flight risks autonomously and increase safety for bystanders while protecting the loss of expensive drones, equipment, and payloads.
About ALLR Allarity Therapeutics Inc.
Allarity Therapeutics Inc is a clinical-stage, precision medicine pharmaceutical company focused on developing novel anti-cancer therapeutics for patients with high unmet medical needs. The company is actively advancing the development of stenoparib, an orally available, small-molecule inhibitor for patients with advanced recurrent ovarian cancer. It is leveraging its proprietary Drug Response Predictor (DRP) technology to refine patient selection and improve clinical outcomes. The company operates as a single operating and reporting segment (developing a treatment for ovarian cancer) in two geographic areas: Denmark and the United States.